Geneva, June 8 -- International Clinical Trials Registry received information related to the study (ISRCTN98606172) titled 'Personalising treatment for myeloma patients based on initial response to NHS treatment and their overall fitness level' on June 1.
Study Type: Interventional
Study Design:
Multi-centre, open-label, phase III platform trial with three randomised-controlled parallel-group components of transplant non-eligible patients with newly diagnosed multiple myeloma (Efficacy, Safety)
Primary Sponsor: University of Leeds
Condition:
Multiple myeloma
plasma cell leukemia (PCL)
Cancer
Intervention:
All participants receive six cycles of standard of care induction treatment with DRd. Each treatment cycle is 28 days.
At the...